Today: 29 April 2026
Estée Lauder stock sinks 21% as 2026 outlook, tariffs rattle investors
5 February 2026
1 min read

Estée Lauder stock sinks 21% as 2026 outlook, tariffs rattle investors

NEW YORK, February 5, 2026, 14:56 (EST) — Regular session.

Shares of The Estée Lauder Companies dropped roughly 21% Thursday, closing at $94.45, down $25.16. Investors digested a full-year forecast that signaled slower growth in its largest market. The stock traded in a wide range, fluctuating between $90.80 and $120.98 during the session.

The scale of the decline is significant given Estée Lauder’s positioning as a turnaround bet—investors were expecting smoother execution, not another sluggish year. Thursday’s selloff zeroed in on the Americas, raising questions about the company’s ability to defend margins amid investments aimed at reigniting growth.

Chief executive Stéphane de La Faverie told Reuters the company is “navigating the complexity and volatility” in the U.S., while noting that Latin America saw slowing consumption after a strong start. Robert Ottenstein, an analyst at Evercore ISI, said the Americas remain a key focus, with sales improving sequentially to flat, though U.S. market share gains didn’t lead to retailer orders. The stock has surged about 40% in 2025. Reuters

Clinique and M.A.C owner Estée Lauder reported fiscal Q2 net sales of $4.229 billion with adjusted EPS at 89 cents, well above the 44 cents in reported earnings. The company raised its fiscal 2026 outlook, factoring in a roughly $100 million tariff impact, mainly in H2. It projects adjusted EPS between $2.05 and $2.25 and an operating margin ranging from 9.8% to 10.2%. Estée Lauder anticipates U.S. import tariffs could reach as high as 39% on select goods. Q3 margins are expected to shrink by about 50 basis points, driven by increased consumer investments and tariff costs. The company reaffirmed its Profit Recovery and Growth Plan, forecasting restructuring expenses between $1.2 billion and $1.6 billion and cutting 5,800 to 7,000 jobs. A quarterly dividend of 35 cents per share will be paid on March 16.

“Adjusted” results leave out items like restructuring and other charges. “Organic” sales remove currency fluctuations and some one-off factors, offering a clearer picture of underlying demand.

The company filed a Form 8-K on Thursday, including the earnings release plus its full-year net sales and EPS projections.

Shares of other U.S.-listed beauty firms also slipped. Coty lost around 9%, while e.l.f. Beauty dipped close to 8%.

But this trade carries plenty of risks. Estée Lauder’s outlook is based on the assumption that geopolitics and consumer sentiment hold steady. It calls out potential pitfalls like retailer destocking, tighter working capital, fiercer competition, and the difficulty of managing outsourcing and restructuring without hurting service levels. Plus, any further changes to trade rules could shift the tariff calculations once again.

As the session winds down, traders eye whether U.S. retailer orders finally align with the company’s market-share assertions. They’re also assessing if the spending on new launches can boost sell-through without causing another margin slip.

The company’s fiscal third-quarter earnings report and conference call are set for May 1 at 8:30 a.m. ET.

Stock Market Today

  • Sensex Rallies 609 Points as Nifty Nears 24,200 on Strong Earnings and Geopolitical Hope
    April 29, 2026, 9:39 AM EDT. Indian benchmark indices rebounded Wednesday with the BSE Sensex rising 609 points (0.79%) to 77,496.36 and the NSE Nifty climbing 182 points (0.76%) to 24,177.65. Gains were broad-based, led by FMCG, auto, and telecom stocks. Maruti Suzuki surged nearly 3% following a record annual net profit, lifted by highest-ever sales and GST rate cuts. Positive earnings reports and easing geopolitical tensions fueled investor sentiment despite elevated crude oil prices which rose 2.85% to $114.4 a barrel. Asian markets also closed higher, reflecting a global mood shift. However, European and U.S. markets remained subdued. Analysts noted improved corporate performance and hopes of reduced global conflicts helped offset macroeconomic concerns and contributed to today's rebound.

Latest article

Biogen Cuts 2026 Profit Forecast After Q1 Beat as Leqembi Sales Surge

Biogen Cuts 2026 Profit Forecast After Q1 Beat as Leqembi Sales Surge

29 April 2026
Biogen lowered its 2026 adjusted earnings forecast to $14.25–$15.25 per share, citing research and development charges from recent acquisitions. First-quarter revenue rose 2% to $2.48 billion, with adjusted earnings of $3.57 per share, beating analyst estimates. Leqembi sales climbed 74% to $168 million globally.
Visa Stock Jumps as Earnings Beat and $20 Billion Buyback Ease Spending Fears

Visa Stock Jumps as Earnings Beat and $20 Billion Buyback Ease Spending Fears

29 April 2026
Visa shares jumped 5% premarket Wednesday after the company beat quarterly profit estimates, raised its full-year outlook, and announced a $20 billion buyback. Adjusted net income rose to $6.3 billion, or $3.31 a share, topping forecasts. Payments volume climbed 9%, cross-border volume 12%. Visa cited resilient consumer spending but flagged Middle East tensions as a risk to travel flows.
Regeneron Earnings Beat, But Eylea Still Clouds REGN Stock

Regeneron Earnings Beat, But Eylea Still Clouds REGN Stock

29 April 2026
Regeneron Pharmaceuticals reported first-quarter revenue of $3.605 billion, up 19%, and adjusted earnings of $9.47 per share, both above analyst estimates. Dupixent sales rose 33% and Libtayo 54%, while total U.S. Eylea sales fell 10%. Shares dropped 1.1% premarket. The FDA delayed a decision on a second Eylea HD syringe manufacturer; Regeneron cut its 2026 gross-margin forecast due to repairs in Ireland.
JNJ stock rises as Johnson & Johnson takes talc shareholder fight to U.S. Supreme Court
Previous Story

JNJ stock rises as Johnson & Johnson takes talc shareholder fight to U.S. Supreme Court

Confluent stock holds near $31 IBM bid as new SEC filing details shareholder suits, Feb. 12 vote
Next Story

Confluent stock holds near $31 IBM bid as new SEC filing details shareholder suits, Feb. 12 vote

Go toTop